Vireo Growth (VREOF) Non-Current Deferred Tax Liability (2025 - 2026)

Vireo Growth (VREOF) reported Non-Current Deferred Tax Liability of $8.1 million for Q1 2026, down 20.59% sequentially from $10.2 million in Q4 2025.

Vireo Growth (VREOF) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends

Vireo Growth (VREOF) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $8.1 million in Q1 2026.

  • For the quarter ending Q1 2026, Non-Current Deferred Tax Liability changed N/A year-over-year to $8.1 million; the trailing twelve-month figure through Mar 2026 stood at $8.1 million (changed N/A YoY), and the FY2025 full-year result was $10.2 million, changed N/A from the prior year.
  • Non-Current Deferred Tax Liability eased to $8.1 million in Q1 2026, from $10.2 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $10.2 million in Q4 2025 to a low of $8.1 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 8.10 Mn
Mar 31, 2026 8.10 Mn
Dec 31, 2025 10.20 Mn
Dec 31, 2025 10.20 Mn